• 专利附录
  • 专利说明
  • 权利要求
  • 类似技术
  • 同族专利
  • 引用文献
  • 法律状态
  • 优先权
    • 专利摘要:
    Summary zinc amino acid / trimethylglycine halide precursor composition The present invention relates to a personal care composition for application to the skin or hair comprising a cosmetically acceptable carrier and zinc halide precursors wherein the precursors are a source. zinc ion source, an x source, and a halide source, wherein the halide source may be part of the zinc ion source, the x source or a halogen acid, where the precursors may complex in the zinc halide. x when the composition is applied to the skin or hair, wherein x is an amino acid or trimethylglycine. Methods of preparing and using the compositions are also provided. When precursors complex into a zinc halide x, the complex can be used to distribute zinc salts to block perspiration and provide antibacterial effects.
    公开号:BR112015014359B1
    申请号:R112015014359-8
    申请日:2012-12-19
    公开日:2019-04-09
    发明作者:Long Pan；Jairajh Mattai；Shamim Ansari；Jianhong Qiu；James G. Masters；Ying Yang
    申请人:Colgate-Palmolive Company；
    IPC主号:
    专利说明:

    [001] Antiperspirants based on aluminum or aluminum / zirconium salts are known. These materials act as antiperspirants when covering the pores, thus blocking the release of sweat. Antiperspirant compositions containing aluminum or aluminum zirconium salts tend to exhibit the polymerization of these salts over time, forming species with molecular weights ranging from about 500 to about 500,000 g / mol. In general, species with lower molecular weight have a greater antiperspirant effect than species with higher molecular weight. Without being limited by theory, it is believed that smaller molecules more readily and efficiently clog sweat pores, thereby producing the desired antiperspirant effect. Keeping a relatively low molecular weight and avoiding excessive polymerization, it intensifies the antiperspirant effect and, in addition, decreases the amount of antiperspirant salt that is necessary to control sweating.
    [002] Underarm deodorants control odor by eliminating the bacteria that cause the odor. Conventional antiperspirant salts tend to be acidic in the aqueous solution, a property that makes them effective bactericides, thereby providing a deodorant benefit, but which can also cause skin irritation.
    [003] There is a need for additional antiperspirant active agents that provide complex weight
    Petition 870190000222, of 01/02/2019, p. 6/38
    2/25 molecular in a size capable of plugging pores to block sweat, which provide deodorant / antibacterial efficacy and which are less irritating to the skin than acid salts in conventional antiperspirants.
    Brief Summary of the Invention [004] The invention provides a composition for personal care, for example, an antiperspirant or deodorant composition, which distributes a zinc halide X, that is, a zinc ion complex, an X residue, on the skin and halide ion, such as zinc chloride and lysine (ZnLisin2Cl2 or ZnLisin3Cl2), for example, where X refers to amino acid or trimethylglycine. In one embodiment, the invention provides a composition comprising zinc halide X and / or zinc halide precursor materials X that form a zinc halide X at the site (for example, the zinc ion source plus a halide amino acid or halide of zinc plus an amino acid or trimethylglycine or source of zinc ion plus halogen acid plus amino acid or trimethylglycine). The source of zinc ion to produce zinc halide X is a material that can release Zn 2+ in aqueous solution in the presence of an amino acid or trimethylglycine, for example, zinc oxide or tetrabasic zinc chloride. Since the zinc halide X provides antibacterial properties, the invention also encompasses other compositions for personal care for application to the skin, for example, hand soaps or body cleaners, comprising a zinc halide X and / or precursors of the same. The invention further provides sweat reduction methods including applying the composition to the
    Petition 870190000222, of 01/02/2019, p. 7/38
    3/25 skin and methods of killing bacteria including contact of bacteria with the composition. Trimethylglycine as used throughout this report refers to Ν, Ν, imtrimethylglycine.
    [005] Other areas of applicability of the present invention will become apparent from the detailed description provided below. It should be understood that the detailed description and specific examples, while indicating the preferred embodiment of the invention, are intended for purposes of illustration only and are not intended to limit the scope of the invention.
    Detailed Description of the Invention [006] The following description of the preferred embodiments is merely exemplary in nature and is in no way intended to limit the invention, its application or uses.
    [007] The invention therefore provides, in one embodiment, a personal care composition for application to the skin or hair comprising a cosmetically acceptable vehicle and zinc halide precursors X in which the precursors are a source of zinc ion, a source X and a halide source, where the halide source can be part of the zinc ion source, the X source, or a halogen acid, where the precursors can complex into the zinc halide X when the composition is applied on the skin or hair. (Composition 1), for example,
    1.1. Any of the foregoing compositions, wherein the source of zinc ion is at least one of zinc oxide, zinc chloride, tetrabasic zinc chloride, zinc carbonate, zinc nitrate, zinc citrate and zinc phosphate.
    Petition 870190000222, of 01/02/2019, p. 8/38
    4/25
    1.2. Any of the above compositions, where the source of the amino acid is at least one of a basic amino acid, lysine, arginine and glycine.
    1.3. Any of the foregoing compositions, in which the precursors are zinc oxide and a halide amino acid.
    1.4. Any of the above compositions, in which the precursors are tetrabasic zinc chloride and at least one of an amino acid, a halide or trimethylglycine amino acid, optionally, zinc halide X is made by combining TBZC with lysine, lysine chloride or trimethylglycine .
    1.5. Any an of the compositions previous, in what O zinc halide X is formed, in whole or in part, at the place after composition to be formulated. 1.6. Any an of the compositions previous, in what O zinc halide X formed from the precursors has The formula ZnLisina2Cl2 or ZnLisina3Cl2, where Zn it's ion in divalent zinc, X it's waste amino acid or trimethylglycine and Hal is halide ion. 1.7. Any an of the compositions previous, in what O amino acid is lysine.1.8. Any an of the compositions previous, in what O zinc halide X it is present in a amount in 0.05 The
    % by weight of the composition, optionally at least 0.1, at least 0.2, at least 0.3, at least 0.4, at least 0.5, at least 1, at least 2, at least 3, or at least 4 to 40% by weight of the composition or, optionally, 0.1 to 30%, up to 20%, up to 10%, up to 5%, up to 4%, up to 3%, up to 2% or up to 1% by weight composition.
    1.9. Any of the previous compositions, in which the
    Petition 870190000222, of 01/02/2019, p. 9/38
    5/25 source X is present in an amount of 0.05 to 30% by weight of the composition, optionally at least 0.1, at least 0.2, at least 0.3, at least 0.4, at least 0 , 5, at least 1, at least 2, at least 3, at least 4, at least 5, at least 10, at least 15, at least 20 to 30% by weight.
    1.10. Any of the foregoing compositions, in which zinc oxide and halide amino acid are present in amounts such that if combined in zinc halide X, zinc halide X would be present in an amount of 0.05 to 40% by weight of the composition , optionally at least 0.1, at least 0.2, at least 0.3, at least 0.4, at least 0.5, at least 1, at least 2, at least 3, or at least 4 through 40 % by weight of the composition or, optionally, 0.1 to 30%, up to 20%, up to 10%, up to 5%, up to 4%, up to 3%, up to 2% or up to 1% by weight of the composition.
    1.11. Any of the foregoing compositions, wherein a molar ratio of zinc to amino acid or trimethylglycine is 2: 1 to 1: 4, optionally 1: 1 to 1: 4, 1: 2 to 1: 4, 1: 3 to 1: 4 , 2: 1 to 1: 3, 2: 1 to 1: 2, 2: 1 to 1: 1 or 1: 3.
    1.12. Any of the above compositions, where a total amount of zinc present in the composition is 0.05
    to 10% in Weight. 1.13. Any an of compositions previous, in that the halide is selected of group consisting of chloride, bromide and iodide. 1.14. Any an of compositions previous, in that the
    zinc halide X formed from the precursors is zinc chloride and lysine.
    1.15. Any of the previous compositions, in a
    Petition 870190000222, of 01/02/2019, p. 10/38
    6/25 anhydrous vehicle.
    1.16. Any of the above compositions, which is an anhydrous composition comprising zinc oxide and halide acid.
    1.17. Any of them of compositions previous, in what O halide is chloride. 1.18. Any of them of compositions previous, in what O amino acid is lysine. 1.19. Any of them of compositions previous, in what O
    zinc halide X formed from the precursors is zinc chloride and lysine (ZnLisina2Cl2 or ZnLisina3Cl2).
    1.20. Any of the above compositions, in a cosmetically acceptable base suitable for application to the skin, for example, a cosmetically acceptable base comprising one or more of water-soluble alcohols (such as C2-8 alcohols including ethanol); glycols (including propylene glycol, dipropylene glycol, tripropylene glycol and mixtures thereof); glycerides (including mono-, di- and triglycerides); medium to long chain organic acids, alcohols and esters; surfactants (including emulsifying and dispersing agents); additional amino acids; structuring agents (including thickening agents and gelling agents, for example, polymers, silicates and silicon dioxide); emollients; fragrances; and dyes (including dyes and pigments).
    1.21. The above composition in which the cosmetically acceptable base is anhydrous, for example, comprises less than 5% water.
    1.22. Any of the previous compositions, in which the composition is an antiperspirant and / or deodorant, for
    Petition 870190000222, of 01/02/2019, p. 11/38
    7/25 example, an antiperspirant stick deodorant, an aerosol antiperspirant spray or a liquid rollon antiperspirant.
    1.23. Any of the above compositions 1-20, wherein the composition is a body cleanser, a shower gel, a bar of soap or a hair conditioner.
    [008] The invention further provides methods of reducing sweating comprising applying an effective antiperspirant amount of any Composition 1, et seq. on the skin, methods of reducing body odor comprising applying an effective deodorant amount of any of Composition 1, et seq. on the skin and methods of killing bacteria comprising contacting the bacteria with an antibacterially effective amount of a composition, for example, any of Composition 1, et seq.
    [009] The invention further provides a method of preparing a composition comprising the combination of zinc halide X precursors wherein the precursors are a zinc ion source, an X source, and a halide source, wherein the halide source may be part of the zinc ion source, the X source or a halogen acid in a cosmetically acceptable base material.
    [0010] The invention further provides a method of forming a zinc halide X comprising applying a composition, for example, any of Compositions 1, et seq. to skin or hair.
    [0011] The invention also provides (i) the use of zinc precursors to form a zinc halide X to kill bacteria, reduce sweating and / or reduce
    Petition 870190000222, of 01/02/2019, p. 12/38
    8/25 body odor, where the precursors are a zinc ion source, an X source, and a halide source, where the halide source can be part of the zinc ion source, the X source or an acid of halogen.
    [0012] Without wishing to be bound by theory, it is believed that the formation of zinc halide X proceeds through the formation of zinc halide then the coordination of amino acid residues around a central zinc. Using the reaction of zinc oxide with lysine chloride in water as an example, ZnO reacts with lysine-HCl by dissociating the hydrochloride to allow the
    reaction: ZnO + HC1 7 ZnCl 2 + H2O. One mole ZnCl 2 will react with 3 moles in lysine for form one transparent solution of complexin Zn-lysine- chloride (ZnLisina2C12 or ZnLisina3C12O which is believed to have the structure described in the formula 1 r in would you like denotes the side chain of amino acid:Γ>Roç O0 00 —ç 2+ | ψ Zn - 0 -N-K RRCl 2 Formula 1 [0013]In this configuration, Zn is located in a
    octahedral center coordinated with two oxygen and two nitrogen atoms in the equatorial plane coming from two lysine carboxylic acids and amine groups, respectively. Zinc is also coordinated with the third lysine through its nitrogen and carboxylic oxygen, at the apical position of the
    Petition 870190000222, of 01/02/2019, p. 13/38
    9/25 metal geometry. This appears to be the dominant complex. Other zinc and lysine complexes are possible, for example, if there is enough halide, for example, ZnOLys2, having a pyramid geometry, with the equatorial plane being the same as the compound above (Zn is linked to two oxygen atoms and two of nitrogen from different lysines), in which the surface of the pyramid is occupied by an O atom. The more complex structures involving multiple zinc ions are also possible, based on the structure of TBZC. Zinc can also have the zinc structure present in zinc stearate.
    [0014] The interaction of zinc and amino acid or trimethylglycine converts the insoluble ZnO or TBZC into a highly soluble complex at approximately neutral pH. In the sweat duct, which contains charged molecules such as proteins and fatty acids, the complex will flocculate the formation of a precipitate that blocks the sweat ducts. As the complex is disrupted under these conditions, releasing free zinc ions, the zinc ions can hydrolyze to form an amorphous zinc hydroxide precipitate, still blocking the ducts and, in addition, the zinc ions can kill bacteria in armpits, thereby reducing underarm odor. An advantage over conventional aluminum or aluminum / zirconium antiperspirant salts is that the complex is formed at an almost neutral pH, while conventional antiperspirant salts are acidic, which can cause skin irritation.
    [0015] It will be understood that other amino acids can be used in place of lysine in the previous scheme. It will also be understood that although zinc, amino acid or
    Petition 870190000222, of 01/02/2019, p. 14/38
    10/25 trimethylglycine and halide may be mainly in the form of precursor materials or in the form of a complex, there may be some degree of equilibrium, so that the proportion of material that is currently in the complex compared to the proportion in the precursor form may vary depending on precise formulation conditions, concentration of materials, pH, presence or absence of water, presence or absence of other charged molecules, and so on.
    [0016] Zinc halide precursors X, for example, ZnO and lysine chloride in the example set out above, can be incorporated in a suitable base, for example, a stick or anhydrous aerosol. Upon sweating, the soluble zinc X halide complex is formed, which can reduce sweat and odor as described above. Alternatively, the soluble complex can be incorporated into a product having an aqueous base, such as a roll-on or spray, to reduce sweat and odor.
    [0017] As used here, the term antiperspirant can refer to any material that may form a plug in a pore to reduce perspiration or antiperspirant refers to those materials classified as Antiperspirants by the Food and Drug Administration under 21 CFR part 350. Antiperspirants as well they can be deodorants, particularly in the case of this invention, since zinc halide X has antibacterial properties and can reduce odor-causing bacteria on the skin.
    [0018] The precursors, which can react on the spot with water to form the zinc halide X. In one embodiment, the zinc halide X can be prepared at
    Petition 870190000222, of 01/02/2019, p. 15/38
    11/25 room temperature by mixing the precursors in a solution, such as water. On-site training provides ease of formulation. The precursors can be used instead of first having to form the zinc halide X. In another embodiment, the water that allows the formation of the zinc halide X of the precursor comes from the sweat that comes into contact with the composition after application.
    [0019] The combination of zinc, X and halide forms a halide salt - cationic complex. Zinc halide X is a water-soluble complex formed from the zinc halide acid addition salt (eg zinc chloride) and an amino acid or the halide acid addition salt from an amino acid (eg lysine hydrochloride) ) and zinc ion source, for example, zinc oxide or TBZC and / or the combination of all three of a halogen acid, an amino acid and a zinc ion source.
    [0020] The source of zinc ion for the combination with a halidric amino acid or an X plus halogen acid can be from any source that efficiently provides Zn 2+ ions, for example, zinc oxide, zinc chloride, zinc chloride tetrabasic, zinc carbonate, zinc nitrate, zinc citrate and zinc phosphate. Zinc oxide is a white powder, insoluble in water. Tetrabasic zinc chloride (TBZC) or zinc chloride hydroxide monohydrate is a zinc hydroxy compound with the formula Zn5 (OH) 8Cl2.H2O also referred to as a basic zinc chloride, zinc hydroxychloride or zinc oxychloride. It is a colorless, crystalline solid, insoluble in water. Both of these materials have been found to be soluble in water in the presence of an amino acid and provide a source of ions of
    Petition 870190000222, of 01/02/2019, p. 16/38
    12/25 zinc while restricting the available anions, since an excess of anions can interfere with the formation of the complex.
    [0021] The source of the amino acid can be any amino acid. Examples of amino acids include, but are not limited to, common natural amino acids, for example: lysine, arginine, histidine, glycine, serine, threonine, asparagine, glutamine, cysteine, selenocysteine, proline, alanine, valine, isoleucine, leucine, methionine, phenylalanine , tyrosine, tryptophan, aspartic acid and glutamic acid.
    [0022] In some modalities, the amino acid is a basic amino acid. By basic amino acid is meant the naturally occurring basic amino acids, such as arginine, lysine, and histidine, as well as any basic amino acid having a carboxyl group and an amino group in the molecule, which is soluble in water and provides an aqueous solution with a pH about 7 or higher. Consequently, basic amino acids include, but are not limited to, arginine, lysine, citrulline, ornithine, creatine, histidine, diaminobutanoic acid, diaminopropionic acid, salts thereof or combinations thereof. In certain embodiments, the amino acid is lysine. In other embodiments, the amino acid is arginine. Neutral amino acids, such as glycine and even acidic amino acids, such as aspartic acid, however, are also capable of forming salts with strong acids, such as halogen acids. In some embodiments, the amino acid is a neutral or acidic amino acid, for example, glycine.
    [0023] The halide source may be part of the source of
    Petition 870190000222, of 01/02/2019, p. 17/38
    13/25
    zinc, such how chloride zinc or chloride in zinc tetrabasic. THE halide source Can be part of amino acid, such as a amino acid halide. Gives same
    way, the halide source can be a halogen acid. The halide can be chlorine, bromine or iodine, more typically chlorine. The acid addition salt of an amino acid and a halogen acid (for example, HCl, HBr or HI) is sometimes referred to here as a halide amino acid. Thus an example of a halide acid is lysine hydrochloride.
    [0024] In certain embodiments, the amount of zinc halide X in the composition is 0.05 to 10% by weight of the composition. In certain embodiments, precursors, for example, zinc oxide and halide amino acid, are present in amounts such that when combined in zinc halide X, zinc halide X would be present in an amount of 0.05 to 10% by weight composition. In both of these embodiments, the amount of the zinc halide X can be varied as to the desired purpose, such as an antibacterial agent or as an antiperspirant. In other embodiments, the amount of zinc halide X is at least 0.1, at least 0.2, at least 0.3, at least 0.4, at least 0.5, at least 1, at least 2, at least 3, or at least 4 to 10% by weight of the composition. In other embodiments, the amount of zinc halide X is less than 9, less than 8, less than 7, less than 6, less than 5, less than 4, less than 3, less than 2, less than 1, less than 0.5 to 0.05% by weight of the composition. In other embodiments, the amounts are 0.05 to 5%, 0.05 to 4%, 0.05 to 3%, 0.05 to 2%, 0.1 to 5%, 0.1 to 4%, 0 , 1 to 3%, 0.1 to 2%, 0.5 to 5%, 0.5 to 4%, 0.5 to 3% or 0.5 to
    Petition 870190000222, of 01/02/2019, p. 18/38
    14/25
    2% by weight of the composition.
    [0025] In certain embodiments, the source of zinc ion, such as zinc oxide or TBZ, is present in an amount of 0.05 to 10% by weight of the composition. In other embodiments, the amount of zinc ion source is at least 0.1, at least 0.2, at least 0.3, at least 0.4, at least 0.5, at least 1, at least 2 at least 3, or at least 4 to 10% by weight of the composition. In other modalities, the amount of zinc oxide or TBZ is less
    than 9, smaller of what 8, smaller of what 7, smaller than 6, smaller than 5, smaller than 4, smaller of than 3, less of that 2, smaller of what 1, smaller than what 0.5 The 0.05% by weight gives
    composition. In other modalities, the quantities are 0.05
    at 5%, 0.05 at 4%, 0.05 to 3%, 0.05 to 2%, 0.1 to 5%, 0.1 to 4%, 0.1 to 3%, 0.1 to 2%, 0.5 to 5%, 0.5 to 4%, 0, 5 to 3% or 0.5 to 2% in Weight composition. [0026] In certain modalities, the source X is
    present in an amount of 0.05 to 30% by weight. In other embodiments, the amount is at least 0.1, at least 0.2, at least 0.3, at least 0.4, at least 0.5, at least 1, at least 2, at least 3, at least at least 4, at least 5, at least 10, at least 15, at least 20 to 30% by weight. In other modalities, the quantity is less than 30, less than 25, less than 20, less than 15, less than 10, less than 5, less than 4, less than 3, less than 2 or less than 1 to 0.05% by weight of the composition.
    [0027] Where precursor materials are present, they are preferably present in molar ratios approximately as required to produce the halide
    Petition 870190000222, of 01/02/2019, p. 19/38
    15/25 of desired zinc X, although an excess of one material or another may be desirable in certain formulations, for example, to balance the pH against other constituents of the formulation, to provide additional antibacterial zinc or to provide buffer X. Preferably, in the However, the amount of halide is limited, since restricting the level of halide in some way stimulates the interaction between zinc and X. For example, in a modality to produce zinc chloride and lysine (ZnLsisina2Cl2 or ZnLisina3Cl2), the reasons molar elements in the precursor materials would include about 1 molar equivalent Zn 2+ : 3 molar equivalents Lys: 2 molar equivalents Cl.
    [0028] In some embodiments, the total amount of zinc in the composition is 0.05 to 10% by weight of the composition. In other embodiments, the total amount of zinc is at least 0.1, at least 0.2, at least 0.3, at least 0.4, at least 0.5 or at least 1 to 8% by weight of the composition . In other embodiments, the total amount of zinc in the composition is less than 5, less than 4, less than 3, less than 2, or less than 1 to 0.05% by weight of the composition.
    [0029] In certain embodiments, a molar ratio of zinc to X is at least 2: 1. In other embodiments, the molar ratio is at least 1: 1, at least 1: 2, at least 1: 3, at least 1: 4, 2: 1 to 1: 4, 1: 1 to 1: 4, 1: 2 to 1: 4, 1: 3 to 1: 4, 2: 1 to 1: 3, 2: 1 to 1: 2, 2: 1 to 1: 1 or 1: 3. Above 1: 4, zinc is expected to be fully dissolved.
    [0030] In certain embodiments, the composition is anhydrous. Per anhydrous, there is less than 5% by weight in water, optionally less than 4, less than 3, less than
    Petition 870190000222, of 01/02/2019, p. 20/38
    16/25
    2, less than 1, less than 0.5, less than 0.1 to 0% by weight of water.
    [0031] When provided in an anhydrous composition, precursors, for example, zinc oxide or TBZC and X, will not react significantly to form zinc halide X. When contacted with a sufficient amount of water, which may be in the form of sweat , the precursors will then react to form the zinc halide X. The zinc halide X when introduced into a sweat duct will flocculate with protein and / or hydrolyze with water and / or sweat to form a precipitate to block the sweat duct.
    [0032] In certain embodiments, zinc halide X may have a conductivity greater than 8000, optionally greater than 9000, greater than 10,000 or greater than 12,000 μβ / cm, preferably when the pH is at least 4.
    [0033] The composition can be any type of composition. In certain embodiments, the composition is any composition in which it is desired to include an antibacterial agent for application to the skin. Examples of such compositions include, but are not limited to, personal care compositions, antiperspirants, deodorants, body cleansers, shower gels, bar soaps, shampoo, hair conditioners, cosmetics.
    [0034] The vehicle represents all other materials in the composition other than zinc halide X or zinc salt and X. The amount of vehicle is then the amount to reach 100% by adding to the weight of zinc halide X or zinc salt and X.
    [0035] For antiperspirant compositions /
    Petition 870190000222, of 01/02/2019, p. 21/38
    17/25 deodorants, the vehicle can be any vehicle that is used for antiperspirants / deodorants. The vehicle can be in the form of a stick, a gel, a roll-on or an aerosol. For stick formulations, the carrier may include oils and / or silicones and gelling agents. An example of a formulation can be found in US2011 / 0076309A1, incorporated by reference here.
    [0036] Optional ingredients that can be included in an antiperspirant and / or deodorant formulation of the compositions of the invention include solvents; water-soluble alcohols such as C2-8 alcohols including ethanol; glycols including propylene glycol, dipropylene glycol, tripropylene glycol and mixtures thereof; glycerides including mono-, di- and triglycerides; medium to long chain organic acids, alcohols and esters; surfactants including emulsifying and dispersing agents; amino acids including glycine; structuring agents including thickening agents and gelling agents, for example, polymers, silicates and silicon dioxide; emollients; fragrances; and dyes including dyes and pigments. If desired, an additional antiperspirant and / or deodorant to zinc halide X can be included, for example, an odor reducing agent such as a sulfur precipitating agent, for example, copper gluconate, zinc gluconate, citrate zinc, etc.
    [0037] Antiperspirant compositions can be formulated in topical antiperspirant and / or deodorant formulations suitable for application to the skin, illustratively a stick, a gel, a cream, a roll-on, a soft solid, a powder, a liquid , an emulsion, a
    Petition 870190000222, of 01/02/2019, p. 22/38
    18/25 suspension, dispersion or spray. The composition can comprise a single phase or it can be a multi-phase system, for example, a system comprising a polar phase and an oil phase, optionally in the form of a stable emulsion. The composition can be liquid, semi-solid or solid. The antiperspirant and / or deodorant formulation can be provided in any suitable container such as an aerosol, can, tube or container with a porous lid, roll-on container, bottle, container with an open end, etc.
    [0038] The compositions can be used in a method to reduce perspiration by applying the composition to the skin. In certain modalities, the application is in the armpit. Likewise, compositions can be used to kill bacteria by contact of bacteria with the composition. For example, in one embodiment, the combination of the amino acid or halide amino acid with zinc oxide increases the availability of zinc ions, which can then kill bacteria and reduce sweat.
    [0039] Thus, the invention provides (i) a method for controlling sweating comprising applying an effective antiperspirant amount to the skin of a formulation of any modality covered or described specifically here, for example, any of Compositions 1 et seq . ; and (ii) a method for controlling the perspiration odor comprises applying to the skin an effective deodorant amount of a formulation of any modality covered or described specifically here, for example, any of Compositions 1 et seq.
    [0040] Unless otherwise stated, all
    Petition 870190000222, of 01/02/2019, p. 23/38
    19/25 the percentages of components of the composition given in this specification are by weight based on a total weight of the composition or formulation of 100%.
    [0041] Unless specifically identified otherwise, the ingredients for use in the compositions and formulations of the present invention are preferably cosmetically acceptable ingredients. Cosmetically acceptable means suitable for use in a formulation for topical application to human skin. A cosmetically acceptable excipient, for example, is an excipient that is suitable for external application in the amounts and concentrations contemplated in the formulations of this invention and includes, for example, excipients that are Generally Recognized as Safe (GRAS) by the United States Food and Drug Administration .
    [0042] The compositions and formulations as provided herein are described and claimed with reference to their ingredients, as is common in the art. As would be evident to someone skilled in the art, the ingredients may, in some cases, react with each other, so that the actual composition of the final formulation may not correspond exactly to the listed ingredients. Thus, it should be understood that the invention extends to the product of the combination of the listed ingredients.
    Example 1 - Solubilization of zinc by amino acid [0043] The Zn concentration of TBZC is compared with ZnO and TBZC with amino acids. The ingredients are dispersed in water, balanced overnight and the supernatant analyzed for free Zn 2+ by atomic absorption. Table 1 shows the comparison of Zn concentration free of
    Petition 870190000222, of 01/02/2019, p. 24/38
    20/25
    TBZC with ZnO and TBZC mixed with different amino acids.
    [0044] Table 1
    Free zn (ppm) TBZC + arginine (4 + 4%) 1819 TBZC + lysine - HCl (4 + 4%) 6000 TBZC + lysine (4 + 4%) 5000 TBZC (4%) 64, 8 ZnO (4%) 11 ZnO + lysine-HCl (4 + 4%) 21700
    [0045] The concentration of free zinc ion provided by TBZC is somewhat higher than with ZnO. This shows that, although both have low solubility, the TBZC solubility is somehow better than ZnO. The concentration of free Zn is increased dramatically when the amino acid is added. For example, solubility increases 28 times when arginine is added and increases close to 100 times when lysine chloride is mixed with TBZC. Lysine chloride also greatly enhances the solubility of zinc oxide.
    Example 2 - Antibacterial Effects [0046] The zone of inhibition is conducted on several materials: zinc oxide and halide amino acid alone and a mixture formed of zinc oxide and halide acid. The method involves preparing a freshly prepared bacterial culture lawn on TSA (tryptic soy agar) plates. Sterile filter paper discs are seeded with 20 µl of test sample (supernatant or mixture). Filter paper discs coated with the sample are air dried and applied over the bacterial turf on TSA plates. The plates are
    Petition 870190000222, of 01/02/2019, p. 25/38
    21/25 incubated for 20 hours at 37 ° C. The results are shown below in Table 2.
    [0047] Table 2
    Material Sample Zone inhibition (mm) Zone inhibition (mm) Sample dampSample dry S. S. Ç. S. S. Ç. aureus epider xerosis aureus epider xerosis ZnO 4% Supernatant 0 0 0 0 0 0Mixture 7 12 0 7 10 0 Lysine-HCl 23.2% How is it 0 0 0 0 0 0 ZnO 4% + lysine Supernatant 12 23 18 13 22 17 HCl 23.2% Mixture 14 25 19 14 24 18
    [0048] As can be seen from the table, when the zinc amino acid halide is formed, the compositions increase in antibacterial activity compared to zinc oxide alone or halide amino acid alone.
    [0049] Similar antibacterial efficacy is seen when tetrabasic zinc chloride is used in place of zinc oxide as the source of zinc ions. The results are shown in Table 3 below.
    [0050] Table 3
    SampleInhibition zone (mm) S. aureus C. minutissimum Arginine 4%0 0 Lysine 4%0 0 Lysine HCl 4%0 0 TBZC 4% Supernatant 6 7 Mixture 6 7 TBZC 4% + arginine 4% Supernatant 8 12
    Petition 870190000222, of 01/02/2019, p. 26/38
    22/25
    Mixture 7.5 16 TBZC 4% + lysine 4% Supernatant 7 21 Mixture 9 16 TBZC 4% + Lysine HCl 4% Supernatant 9 20 Mixture 7 17
    [0051] As can be seen from the table, when the zinc amino acid halide is formed, the compositions increase in antibacterial activity compared to tetrabasic zinc chloride alone or amino acid alone.
    Example 3: Sweat Reduction Mechanisms [0052] A lysine and zinc chloride (ZLC) is prepared by mixing ZnO + 2 (Lysine-HCl) in the presence of water to yield [Zn (Lysine) 2Cl] + Cl - . 2H2O.
    [0053] Hydrolysis reaction: a solution of 185 mg / ml of ZLC is prepared and diluted several times and aged in an oven at 37 ° C for 5 hours for turbidity studies. A white precipitate forms as the solution is diluted. The turbidity of the solutions is measured using a nephelometer, the results being given in nephelometric turbidity units (NTU). Table 4 shows a comparison of pH and turbidity before and after aging, showing an increase in turbidity with dilution and aging:
    [0054] Table 4
    185mg / ml 92.5mg / ml 46.25mg / ml 23,125mg / ml 11.56mg / ml 5.78mg / ml initial pH 6.8 7 7.4 7.7 7.8 8 Initial turbidity (NTU) 4.7 2.8 1.5 0.7 14.8 40, 1
    Petition 870190000222, of 01/02/2019, p. 27/38
    23/25
    pH after aging 6, 8 7 7.4 7.7 7.8 8 Turbidity afteraging (NTU) 4.1 2.6 2.8 247.4 > 1000 > 1000
    [0055] The precipitates formed in the diluted solutions 8x, 16x and 32x are collected by centrifugation and identified as crystalline ZnO by PXRD. From the supernatant, a single crystal is developed and shown by X-ray diffraction to be lysine dihydrate monohydrochloride (Lysine-HCl-2H2O). These data indicate that the ZLC complex disassociates by dilution, with the consequent precipitation of zinc oxide.
    [0056] The mechanism of the ZLC hydrolysis reaction can be expressed as:
    [Zn (Lysine) 2Cl] + Cr - .2H2O + H2O-> ZnO + Lysine HCl.2H2O [0057] In a product for the armpits, a mixture of ZnO + lysine HCl, in the presence of sweat, will form ZLC, which will enter in the sweat duct and will form a ZnO plug.
    [0058] Flocculation: Another mechanism by which the ZLC blocks the release of sweat involves the flocculation of ZLC in the presence of protein. Bovine serum albumin (BSA) is used as the protein in this study. The control solution (DI water) and three aqueous solutions of 1% BSA with different pH are prepared as shown in table 5:
    [0059] Table 5
    Sample 1 Sample 2 Sample 3 H2O 15 ml 15 ml 15 ml BSA 0 g 155.1 mg 155.2 mg 5 BSA p / p 0% 1% 1% pH 6.4 7.2 Adjusted to5.1
    Petition 870190000222, of 01/02/2019, p. 28/38
    24/25
    Turbidity (NTU) 0.35 3, 6 10, 6 Note Transparent Transparent Transparent
    [0060] The ZLC powder is added to the above samples to study the interaction between ZLC and BSA and to determine when ZLC has astringent properties, that is, when it can form a precipitate and thus behave like an antiperspirant. Turbidity and pH of solutions are measured 5 hours after the mixtures are placed in a 37 ° C oven and the results are shown in table 6.
    [0061] Table 6
    Sample 1 Sample 2 Sample 3 ZLC added 151.1 mg 151.1 mg 150.9 mg Concentration About About 0.96% About 0.96% w / w of ZLC in 0.98% w / w or w / w or 15 mg / ml or 15 mg / ml solution 15 mg / ml Note The solution A precipitate A precipitatetransparent very white if very white ifbecomes formed, the solution formed, the solutionslightly becomes very becomes veryblurred. blurred. blurred. pH 8 8.2 8 Turbidity (NTU) 357 > 1000 > 1000
    [0062] Thus, in the sweat duct (pH = 5-7), ZLC will hydrolyze in insoluble ZnO to physically block the sweat ducts. In addition, ZLC also has the ability to flocculate proteins, such as BSA, in sweat, thereby intensifying the formation of sweat duct plugs.
    [0063] As used throughout this report, ranges are used as an abbreviation to describe each value that falls within the range. Any value within the range
    Petition 870190000222, of 01/02/2019, p. 29/38
    25/25 can be selected as the end of the track. In addition, all references cited herein are hereby incorporated by reference in their entirety. In the event of a conflict in a definition in this description and in that of a cited reference, this description has priority.
    [0064] Unless otherwise specified, all percentages and quantities expressed here and elsewhere in the specification should be understood as referring to percentages by weight. The quantities given are based on the active weight of the material.
    权利要求:
    Claims (15)
    [1]
    1. Anhydrous personal care composition for application to the skin or hair, FEATURED by the fact that it comprises a cosmetically acceptable anhydrous vehicle, and zinc halide precursors X, in which the precursors are a source of zinc ion, a source X and a halide source, where the halide source can be part of the zinc ion source, the X source or a halogen acid, where the precursors can complex into the zinc halide X when the composition is applied to the skin or hair and act as an antiperspirant, where X is an amino acid or trimethylglycine, and where the precursors are present in amounts such that when combined in the zinc halide X, the zinc halide X would be present in an amount of 0.05 to 10% by weight of the composition.
    [2]
    2. Personal care composition according to claim 1, CHARACTERIZED by the fact that the source of zinc ion is at least one of zinc oxide, zinc chloride, tetrabasic zinc chloride, zinc carbonate, zinc, zinc citrate and zinc phosphate.
    [3]
    3. Composition for personal care, according to claim 1 or 2, CHARACTERIZED by the fact that the source of amino acid is at least one among a basic amino acid, lysine, arginine and glycine.
    [4]
    4. Personal care composition, according to any one of claims 1 to 3, CHARACTERIZED by the fact that the precursors are zinc oxide with a halide amino acid.
    [5]
    5. Composition for personal care, according to
    Petition 870190000222, of 01/02/2019, p. 31/38
    2/4 any one of claims 1 to 3, CHARACTERIZED by the fact that the precursors are tetrabasic zinc chloride with an amino acid, a halide acid, or trimethylglycine, optionally the amino acid is selected from the basic amino acid, lysine, arginine and glycine .
    [6]
    6. Personal care composition according to any one of claims 1 to 5, CHARACTERIZED by the fact that the zinc halide X formed from the precursors has the formula ZnX3Hal2, where Zn is a divalent zinc ion, and Hal is a halide ion.
    [7]
    7. Personal care composition according to any one of claims 1 to 6, CHARACTERIZED by the fact that the total amount of zinc present in the composition is 0.05 to 8% by weight.
    [8]
    8. Personal care composition according to any one of claims 1 to 7, CHARACTERIZED by the fact that the zinc ion source X is present in an amount of 0.05 to 10% by weight of the composition, optionally by at least 0.1, at least 0.2, at least 0.3, at least 0.4, at least 0.5, at least 1, at least 2, at least 3 or at least 4 to 10% by weight of composition.
    [9]
    9. Personal care composition according to any one of claims 1 to 8, CHARACTERIZED by the fact that the source X is present in an amount of 0.05 to 30% by weight of the composition, optionally at least 0.1 , at least 0.2, at least 0.3, at least 0.4, at least 0.5, at least 1, at least 2, at least 3, at least 4, at least 5, at least 10, at least at least 15, at least 20 to 30% by weight.
    Petition 870190000222, of 01/02/2019, p. 32/38
    3/4
    [10]
    10. Personal care composition according to any one of claims 1 to 9, CHARACTERIZED by the fact that a molar ratio of zinc to X is 2: 1 to 1: 4, optionally 1: 1 to 1: 4, 1 : 2 to 1: 4, 1: 3 to 1: 4, 2: 1 to 1: 3, 2: 1 to 1: 2, 2: 1 to 1: 1, or 1: 3.
    [11]
    11. Personal care composition according to any one of claims 1 to 10, CHARACTERIZED by the fact that the zinc halide X formed from the precursors is lysine zinc chloride, optionally the zinc halide X formed from the precursor is ZnLisina2Cl2 or ZnLisina3Cl2.
    [12]
    12. Personal care composition according to any one of claims 1 to 11, CHARACTERIZED by the fact that zinc halide X is formed, in whole or in part, in place (“in situ) after the composition is formulated .
    [13]
    13. Personal care composition according to claim 12, CHARACTERIZED by the fact that the cosmetically acceptable base comprises one or more ingredients selected from water-soluble alcohols; glycols; glycerides; medium to long chain organic acids, alcohols and esters; surfactants; additional amino acids; structuring; emollients; fragrances; and colorants.
    [14]
    14. Composition for personal care, according to any one of claims 1 to 13, CHARACTERIZED by the fact that the composition is an antiperspirant and a deodorant, optionally the composition is a body cleansing product, a shower gel, a soap bar, a shampoo, or hair conditioner.
    [15]
    15. Use of zinc precursors to form a halide
    Petition 870190000222, of 01/02/2019, p. 33/38
    4/4 zinc X, CHARACTERIZED by the fact that it is in the preparation of an anhydrous composition for personal care, as defined in any of claims 1 to 14, to kill bacteria, reduce perspiration, and / or reduce body odor.
    类似技术:
    公开号 | 公开日 | 专利标题
    BR112015014359B1|2019-04-09|ANTIRE PERSONAL CARE COMPOSITION FOR SKIN OR HAIR APPLICATION AND USE OF ZINC PRECURSORS TO FORM A ZINC X HALLET FOR PREPARATION OF SUCH COMPOSITION
    BR112015014501B1|2019-04-02|Personal care composition for skin or hair application and use of a zinc halide complex X
    RU2627840C2|2017-08-14|Antiperspirant products with protein content and antipresspirant salts
    US20190117536A1|2019-04-25|Oral Care Composition Comprising Zinc-Lysine Complex
    BRPI0620810B1|2018-09-18|alcohol-in-oil emulsion comprising a multivalent metal salt
    BR112017012807B1|2020-09-15|COMPOSITION FOR ORAL HYGIENE AND USE OF A SOLUBLE ZINC POLYPHOSPHATE COMPLEX IN THE PREPARATION OF THE SAME
    BR112017013014B1|2020-11-10|personal hygiene composition, and method for depositing zinc on an individual's skin and / or hair
    同族专利:
    公开号 | 公开日
    CA2892179A1|2014-06-26|
    CN104853720B|2017-10-24|
    BR112015014359A2|2017-07-11|
    RU2638791C2|2017-12-15|
    RU2015123753A|2017-01-23|
    AU2012397255A1|2015-06-11|
    MX2015007676A|2015-09-07|
    US20150328095A1|2015-11-19|
    TW201424758A|2014-07-01|
    CA2892179C|2020-03-31|
    WO2014098814A1|2014-06-26|
    AR094071A1|2015-07-08|
    EP2934439A1|2015-10-28|
    MX355285B|2018-04-13|
    TWI548421B|2016-09-11|
    AU2012397255B2|2015-12-03|
    US9925130B2|2018-03-27|
    PH12015501265A1|2015-08-17|
    CN104853720A|2015-08-19|
    HK1216012A1|2016-10-07|
    EP2934439B1|2017-03-08|
    引用文献:
    公开号 | 申请日 | 公开日 | 申请人 | 专利标题
    DE735096C|1940-12-09|1943-05-06|Ig Farbenindustrie Ag|Process for the production of sulphonic acids|
    US2527686A|1945-12-26|1950-10-31|Max H Sandberg|Mouthwash|
    US2503280A|1947-10-24|1950-04-11|Du Pont|Azo catalysts in preparation of sulfonic acids|
    US2507088A|1948-01-08|1950-05-09|Du Pont|Sulfoxidation process|
    US2893918A|1957-04-24|1959-07-07|Harold A Abramson|Deodorant composition|
    FR1247957A|1958-09-28|1960-12-09|Ajinomoto Kk|Process for the continuous separation of racemic amino acids|
    US3320174A|1964-04-20|1967-05-16|Colgate Palmolive Co|Detergent composition|
    US3372188A|1965-03-12|1968-03-05|Union Oil Co|Sulfoxidation process in the presence of sulfur trioxide|
    US3538230A|1966-12-05|1970-11-03|Lever Brothers Ltd|Oral compositions containing silica xerogels as cleaning and polishing agents|
    US3678154A|1968-07-01|1972-07-18|Procter & Gamble|Oral compositions for calculus retardation|
    US3535421A|1968-07-11|1970-10-20|Procter & Gamble|Oral compositions for calculus retardation|
    US3741911A|1970-12-21|1973-06-26|Hart Chemical Ltd|Phosphate-free detergent composition|
    US3959458A|1973-02-09|1976-05-25|The Procter & Gamble Company|Oral compositions for calculus retardation|
    US3937807A|1973-03-06|1976-02-10|The Procter & Gamble Company|Oral compositions for plaque, caries, and calculus retardation with reduced staining tendencies|
    US3862307A|1973-04-09|1975-01-21|Procter & Gamble|Dentifrices containing a cationic therapeutic agent and improved silica abrasive|
    US3941818A|1973-08-20|1976-03-02|Zinpro Corporation|1:1 Zinc methionine complexes|
    US4051234A|1975-06-06|1977-09-27|The Procter & Gamble Company|Oral compositions for plaque, caries, and calculus retardation with reduced staining tendencies|
    US4340583A|1979-05-23|1982-07-20|J. M. Huber Corporation|High fluoride compatibility dentifrice abrasives and compositions|
    US4339432A|1979-06-20|1982-07-13|Lever Brothers Company|Oral mouthwash containing zinc and glycine|
    GB2052978A|1979-06-20|1981-02-04|Unilever Ltd|Oral compositions containing zinc salts|
    US4316824A|1980-06-26|1982-02-23|The Procter & Gamble Company|Liquid detergent composition containing alkyl sulfate and alkyl ethoxylated sulfate|
    JPS57158724A|1981-03-26|1982-09-30|Shiseido Co Ltd|Antimicrobial composition|
    US4565693A|1981-11-09|1986-01-21|Colgate-Palmolive Company|Deodorant composition|
    US4487757A|1981-12-28|1984-12-11|Colgate-Palmolive Company|Dispensing container of toothpaste which effervesces during toothbrushing|
    IL64700D0|1982-01-01|1982-03-31|Binderman Itzhak|Dental care compositions|
    US4885155A|1982-06-22|1989-12-05|The Procter & Gamble Company|Anticalculus compositions using pyrophosphate salt|
    DE3238118C2|1982-10-14|1988-07-28|Verla-Pharm, Arzneimittelfabrik Apotheker H.J. V. Ehrlich Gmbh & Co Kg, 8132 Tutzing, De|
    US4687663B1|1983-03-01|1997-10-07|Chesebrough Ponds Usa Co|Dental preparation article and method for storage and delivery thereof|
    CA1243952A|1984-06-11|1988-11-01|John C. Godfrey|Flavor of zinc supplements for oral use|
    US4599152A|1985-05-24|1986-07-08|Albion Laboratories|Pure amino acid chelates|
    US5192531A|1988-12-29|1993-03-09|Colgate-Palmolive Company|Antibacterial antiplaque oral composition|
    US5188821A|1987-01-30|1993-02-23|Colgate-Palmolive Company|Antibacterial antiplaque oral composition mouthwash or liquid dentifrice|
    US4866161A|1987-08-24|1989-09-12|University Of South Alabama|Inhibition of tartar deposition by polyanionic/hydrophobic peptides and derivatives thereof which have a clustered block copolymer structure|
    US5004597A|1987-09-14|1991-04-02|The Procter & Gamble Company|Oral compositions comprising stannous flouride and stannous gluconate|
    US4842847A|1987-12-21|1989-06-27|The B. F. Goodrich Company|Dental calculus inhibiting compositions|
    US5061815A|1988-07-06|1991-10-29|Zinpro Corporation|Metal lysine complexes and method for producing metal lysine complexes|
    US5156845A|1990-05-04|1992-10-20|Colgate-Palmolive Company|Dry mouth lozenge|
    GB2243775A|1990-05-09|1991-11-13|Unilever Plc|Oral compositions|
    JPH0578243A|1990-12-11|1993-03-30|Shiseido Co Ltd|Antipruritic agent and antipruritic composition|
    GB9107833D0|1991-04-12|1991-05-29|Unilever Plc|Treatment of periodontitis|
    US5643559A|1991-10-30|1997-07-01|Colgate-Palmolive Company|Deodorant compositions comprising inhibitors of odor-producing axillary bacterial exoenzymes|
    US5504055A|1994-03-15|1996-04-02|J.H. Biotech, Inc.|Metal amino acid chelate|
    US5707679A|1994-09-30|1998-01-13|Kemin Industries, Inc.|Metal propionates for use as animal feed supplements|
    EP1203575B1|1995-05-03|2010-09-01|Unilever N.V.|Clear gel-type dentrifices|
    US5714447A|1996-01-24|1998-02-03|Church & Dwight Co., Inc.|Deodorant soap or detergent composition containing a zinc compound and a polyamine|
    US5698724A|1996-04-30|1997-12-16|Zinpro Corporation|Amino acid metal complexes using hydrolyzed protein as the amino acid source and methods re same|
    AU4428397A|1996-09-20|1998-04-14|Warner-Lambert Company|Oral compositions containing a zinc compound|
    GB9622659D0|1996-10-31|1997-01-08|Unilever Plc|Hair treatment composition|
    US5897891A|1996-11-18|1999-04-27|Godfrey; John C.|Flavorful zinc compositions for oral use incorporating copper|
    FI106923B|1997-01-03|2001-05-15|Cultor Ltd Finnsugar Bioproduc|Use of trimethylglycine in preparations for hygiene and care of the mucous membranes of the body|
    US5993784A|1997-07-24|1999-11-30|Whitehill Oral Technologies|Low foaming therapeutic toothpastes with improved cleaning and abrasion performance|
    DK176196B1|1997-10-07|2007-01-08|Ejvind Jersie Pedersen|Oral hygiene composition for the treatment of halitosis and the use of a chelate comprising a metal ion moiety and an amino acid moiety as a component of the composition|
    US5895644A|1997-11-20|1999-04-20|Colgate-Palmolive Company|Clear antiperspirant stick with dibenzylidene sorbitol and guar and process of making same|
    IL140095A|1998-06-09|2005-11-20|Embro William J|Composition for the treatment of epidermal irritations and infections|
    US6558710B1|1999-06-14|2003-05-06|Helen Rebecca Godfrey|Topical zinc compositions and methods of use|
    US6685920B2|1999-11-12|2004-02-03|The Procter & Gamble Company|Method of protecting teeth against erosion|
    US7164035B2|2000-01-07|2007-01-16|Newsome David A|Zinc-monocysteine complex and method of using zinc-cysteine complexes|
    JP3490950B2|2000-03-15|2004-01-26|三洋電機株式会社|2-cylinder 2-stage compression type rotary compressor|
    DE10160933B4|2001-12-12|2018-06-21|Evonik Degussa Gmbh|Deodorizing compositions containing the zinc salt of ricinoleic acid and at least one amino-functional amino acid|
    US6670494B1|2001-12-17|2003-12-30|J H Brotech, Inc.|Method for preparation of metal organic acid chelates|
    US20040033916A1|2002-06-28|2004-02-19|Kuzmin Vladimir Semenovich|Disinfecting composition|
    US6649153B1|2002-09-16|2003-11-18|Reheis Inc.|Skin friendly antiperspirant composition and method of making|
    JP2004175790A|2002-11-12|2004-06-24|Arita Junichi|ZINC-CONTAINING MATERIAL HAVING alpha-GLUCOSIDASE INHIBITORY EFFECT|
    US7022351B2|2003-01-14|2006-04-04|Zinpro Corporation|Composition for supplementing animals with solutions of essential metal amino acid complexes|
    US9381148B2|2003-03-18|2016-07-05|The Procter & Gamble Company|Composition comprising particulate zinc material with a high relative zinc lability|
    US20040198998A1|2003-04-04|2004-10-07|Marian Holerca|Glycine-free antiperspirant salts with betaine for enhanced cosmetic products|
    US7270806B2|2004-07-27|2007-09-18|Coty S.A.|Liquid stick antiperspirant|
    US7700079B2|2005-09-26|2010-04-20|Jamie Collins Doss|Therapeutic soap product with UV protection|
    BRPI0619389A2|2005-11-29|2011-10-04|Procter & Gamble|dentifrice composition comprising a binder system comprising hydrophilic clay material|
    CN100366539C|2006-05-25|2008-02-06|黄逸强|Method for preparing microelement additive basic zinc chloride|
    DE102006040302A1|2006-08-29|2008-03-20|Henkel Kgaa|Antiperspirant and deodorant compositions with improved care properties|
    PL1935395T3|2006-12-20|2013-11-29|Unilever Nv|Oral composition|
    US8247398B2|2007-02-17|2012-08-21|Ssv Therapeutics, Inc.|Zinc complexes of natural amino acids for treating elevated copper caused toxicities|
    JP2009084201A|2007-09-28|2009-04-23|Riken Koryo Kogyo Kk|Deodorization treating agent for permanent waving agent and permanent waving agent comprising the same|
    JP2011519969A|2008-05-12|2011-07-14|タグラバイオテクノロジーズリミテッド|Composition for topical application comprising a microencapsulated colorant|
    US20100021573A1|2008-07-22|2010-01-28|Michael J Gonzalez|Compositions and methods for the prevention of cardiovascular disease|
    JP2010132639A|2008-11-10|2010-06-17|Nikko Chemical Co Ltd|Dna damage inhibitor and matrix metalloprotease-1 production inhibitor|
    KR101595033B1|2009-06-24|2016-02-17|챨스 엔.에스. 소파카|Zinc supplementation to increase responsiveness to metalloprotease therapy|
    CN101606639B|2009-07-20|2012-07-25|曹江山|Nursery pig concentrated feed|
    AU2009353312B2|2009-09-30|2013-04-04|Colgate-Palmolive Company|Antiperspirant/deodorant composition|
    MY159488A|2009-10-29|2017-01-13|Colgate Palmolive Co|Dentifrice comprising stannous fluoride plus zinc citrate and low levels of water|
    TWI458497B|2010-01-13|2014-11-01|Colgate Palmolive Co|Stabilization of zinc oxide film in oral compositions|
    BR112012022935A2|2010-03-31|2021-06-01|Colgate-Palmolive Company|oral hygiene composition.|
    CN103156073B|2011-12-13|2015-02-18|北京东方联鸣科技发展有限公司|Nutritional supplement for postpartum dairy cows|
    CN103535536A|2012-07-15|2014-01-29|新沂市佳威饲料有限公司|Method for preparing lactating sow feed|
    KR20150094651A|2012-12-19|2015-08-19|콜게이트-파아므올리브캄파니|Oral gel comprising zinc - amino acid complex|
    CN104853812B|2012-12-19|2018-07-10|高露洁-棕榄公司|Antiperspirant products with protein and hidroschesis salt|
    US9901523B2|2012-12-19|2018-02-27|Colgate-Palmolive Company|Oral care products comprising zinc oxide and trimethylglycine|
    WO2014098821A1|2012-12-19|2014-06-26|Colgate-Palmolive Company|Method for indicating time for washing or indicating delivery of antibacterial agent|
    KR20150097562A|2012-12-19|2015-08-26|콜게이트-파아므올리브캄파니|Two component compositions containing zinc amino acid halide complexes and cysteine|
    US10494589B2|2012-12-19|2019-12-03|Colgate-Palmolive Company|Method for indicating time for washing or indicating delivery of antibacterial agent|
    WO2014098813A1|2012-12-19|2014-06-26|Colgate-Palmolive Company|Zinc amino acid/trimethylglycine halide|
    CN104853726B|2012-12-19|2017-10-24|高露洁-棕榄公司|Include the oral care product of four basic zinc amino acid halide complex|
    MX352558B|2012-12-19|2017-11-29|Colgate Palmolive Co|Oral care compositions comprising zinc amino acid halides.|
    RU2648513C2|2012-12-19|2018-03-26|Колгейт-Палмолив Компани|Zinc amino acid halide mouthwash|
    MX353167B|2012-12-19|2017-12-20|Colgate Palmolive Co|Teeth whitening methods, visually perceptible signals and compositions therefor|comprising zinc amino acid halides.|
    CA2892179C|2012-12-19|2020-03-31|Colgate-Palmolive Company|Composition with zinc amino acid/trimethylglycine halide precursors|
    US9757316B2|2012-12-19|2017-09-12|Colgate-Palmolive Company|Zinc-lysine complex|
    WO2014204439A1|2013-06-18|2014-12-24|Colgate-Palmolive Company|Zinc amino acid halide complex with cysteine|RU2648513C2|2012-12-19|2018-03-26|Колгейт-Палмолив Компани|Zinc amino acid halide mouthwash|
    WO2014098813A1|2012-12-19|2014-06-26|Colgate-Palmolive Company|Zinc amino acid/trimethylglycine halide|
    MX353167B|2012-12-19|2017-12-20|Colgate Palmolive Co|Teeth whitening methods, visually perceptible signals and compositions therefor|comprising zinc amino acid halides.|
    US9504858B2|2012-12-19|2016-11-29|Colgate-Palmolive Company|Zinc amino acid halide complex with cysteine|
    US10188112B2|2012-12-19|2019-01-29|Colgate-Palmolive Company|Personal cleansing compositions containing zinc amino acid/trimethylglycine halide|
    CN104853812B|2012-12-19|2018-07-10|高露洁-棕榄公司|Antiperspirant products with protein and hidroschesis salt|
    MX352558B|2012-12-19|2017-11-29|Colgate Palmolive Co|Oral care compositions comprising zinc amino acid halides.|
    CN104853726B|2012-12-19|2017-10-24|高露洁-棕榄公司|Include the oral care product of four basic zinc amino acid halide complex|
    US9498421B2|2012-12-19|2016-11-22|Colgate-Palmolive Company|Two component compositions containing tetrabasic zinc-amino acid halide complexes and cysteine|
    US9757316B2|2012-12-19|2017-09-12|Colgate-Palmolive Company|Zinc-lysine complex|
    AU2012397268B2|2012-12-19|2015-09-24|Colgate-Palmolive Company|Oral care products comprising tetrabasic zinc chloride and trimethylglycine|
    KR20150094651A|2012-12-19|2015-08-19|콜게이트-파아므올리브캄파니|Oral gel comprising zinc - amino acid complex|
    US9750670B2|2012-12-19|2017-09-05|Colgate-Palmolive Company|Zinc amino acid complex with cysteine|
    US9901523B2|2012-12-19|2018-02-27|Colgate-Palmolive Company|Oral care products comprising zinc oxide and trimethylglycine|
    CA2892179C|2012-12-19|2020-03-31|Colgate-Palmolive Company|Composition with zinc amino acid/trimethylglycine halide precursors|
    US9675823B2|2012-12-19|2017-06-13|Colgate-Palmolive Company|Two component compositions containing zinc amino acid halide complexes and cysteine|
    EP3157934B1|2014-06-18|2018-10-17|Colgate-Palmolive Company|Low ph synthesis of zinc-lysine complex|
    US10130571B2|2014-06-18|2018-11-20|Colgate-Palmolive Company|Dentifrice Comprising Zinc-Amino Acid Complex and Phosphates|
    WO2015195118A1|2014-06-18|2015-12-23|Colgate-Palmolive Company|Synthesis of zinc-lysine complex from zinc chloride|
    BR112017013008B1|2014-12-26|2020-11-10|Colgate-Palmolive Company|personal hygiene compositions with active zinc phosphate and method for depositing zinc on an individual's skin and / or hair|
    EP3223914B1|2014-12-26|2020-05-06|Colgate-Palmolive Company|Zinc phosphate complex|
    US10058493B2|2016-12-21|2018-08-28|Colgate-Palmolive Company|Oral care compositions and methods of use|
    CN108324583B|2017-12-26|2019-10-18|浙江大学|A method of exciting metal active ion in cosmetics|
    CN108186381B|2017-12-26|2019-09-06|浙江大学|A method of exciting zinc active ion in cosmetics|
    CN113226298A|2018-12-20|2021-08-06|高露洁-棕榄公司|Oral care composition comprising zinc and amino acid for treating symptoms of gastric disorders in the oral cavity|
    EP3897864A1|2018-12-21|2021-10-27|Colgate-Palmolive Company|Zinc-arginine-halide complex|
    US11229591B2|2018-12-21|2022-01-25|Colgate-Palmolive Company|Methods for synthesizing zinc-lysine-chloride complex|
    US11117906B2|2018-12-21|2021-09-14|Colgate-Palmolive Company|Methods for synthesizing zinc-lysine-chloride complex|
    US11091502B2|2018-12-21|2021-08-17|Colgate-Palmolive Company|Methods for synthesizing zinc-lysine-chloride complex|
    法律状态:
    2018-10-02| B15K| Others concerning applications: alteration of classification|Free format text: AS CLASSIFICACOES ANTERIORES ERAM: A61K 8/27 , A61K 8/44 , A61Q 15/00 Ipc: A61K 8/27 (2006.01), A61K 8/20 (2006.01), A61K 8/4 |
    2018-10-02| B07A| Technical examination (opinion): publication of technical examination (opinion)|
    2019-02-12| B09A| Decision: intention to grant|
    2019-04-09| B16A| Patent or certificate of addition of invention granted|Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 19/12/2012, OBSERVADAS AS CONDICOES LEGAIS. (CO) 20 (VINTE) ANOS CONTADOS A PARTIR DE 19/12/2012, OBSERVADAS AS CONDICOES LEGAIS |
    优先权:
    申请号 | 申请日 | 专利标题
    PCT/US2012/070492|WO2014098814A1|2012-12-19|2012-12-19|Composition with zinc amino acid/trimethylglycine halide precursors|
    [返回顶部]